Active Systemic Lupus Erythematosus
6
1
1
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
16.7%
1 terminated out of 6 trials
80.0%
-6.6% vs benchmark
67%
4 trials in Phase 3/4
125%
5 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (6)
Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)
A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)
Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus
Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus